OBJECTIVE:to probe into the efficacy of tirofiban hydrochloride in treatment of acute myocardial infarction patients with no/slow-reflow phenomenon after percutaneous coronary intervention.METHODS:50 patients with acute myocardial infarction admitted into Hezhou People’s Hospital during 2012-2015 were selected as the research objects.Patients with no/slow-reflow phenomenon after percutaneous coronary intervention were set as the observation group;and another 50 patients without no/slow-reflow phenomenon were set as the control group.The obervation group were given tirofiban hydrochloride, while the control group were treated with nadroparin calcium.The related indexes and incidence of adverse drug reactions were compared between two groups after treatment.RESULTS: Before discharge, the LVEF of observation group was (51.26 ±7.35)%, and control group was (50.84 ±6.51)%;patients with E/A>1 of observation group were 18 cases, and control were 13 cases.Ratio of patients with ST segment resolution ≥50% after surgery in observation group was 84.0%( 21/25 ) , and control group was 76.0%( 19/25 ) . Meanwhile, in observation group and control group, the incidence of reperfusion arrythmia after surgery were respectively 12.0%( 3/25 ) and 16.0%( 4/25 ); and improvement rate of angina were respectively 88.0%( 22/25 ) and 80.0%( 20/25 ); the incidence of refractory ischemia after surgery were respectively 0%( 0/25 ) and 8.0%(2/25), the difference was not statistically significant different(P>0.05).After treatment, the blood platelet count of observation group were significantly lower than that of control group, with statistically significant difference ( P<0.05), yet it remained at a normal level and recovered after stopping drugs.There was retroperitoneal bleeding, intracranial hemorrhage, haematemesis and cardiovascular events occurred in two groups after surgery . CONCLUSIONS:The efficacy of tirofiban hydrochloride in treatment of acute myocardial infarction patients with no/slow-reflow phenomenon after percutaneous coronary intervention is significant, which can reduce the incidence of cardiovascular events and help to protect the cardiac function.%目的：探讨盐酸替罗非班治疗急性心肌梗死直接经皮冠状动脉介入术后无／慢复流患者的疗效。方法：选取2012—2015年在贺州市人民医院接受治疗的50例急性心肌梗死患者为研究对象。其中，25例患者经皮冠状动脉介入治疗后出现无／慢复流现象，为观察组；其余25例患者未出现无／慢复流现象，为对照组。观察组患者给予盐酸替罗非班，对照组患者给予那屈肝素钙。比较2组患者治疗后相关指标水平及不良反应发生情况。结果：出院前，观察组患者左心室射血分数为（55．26±7．35）％，对照组为（51．84±6．51）％；观察组18例患者舒张早期血流峰速度／舒张晚期血流峰速度＞1，对照组为13例；观察组术后2 h心电图ST段回落≥50％患者所占比例为84．0％（21／25），对照组为76．0％（19／25）；观察组术后再灌注心律失常发生率为12．0％（3／25），对照组为16．0％（4／25）；观察组患者术后心绞痛改善率为88．0％（22／25），对照组为80．0％（20／25）；观察组患者术后顽固性缺血发生率为0％（0／25），对照组为8．0％（2／25），2组的差异均无统计学意义（P＞0．05）。治疗后，观察组患者血小板计数明显低于对照组，差异有统计学意义（ P＜0．05），但仍处于正常水平，经停药处理后得以恢复。2组患者均未出现腹膜后出血、颅内出血、呕血等，术后均未发生心血管事件。结论：盐酸替罗非班治疗直接经皮冠状动脉介入术后无／慢复流患者，疗效显著，可减少心血管事件的发生，对保护心脏功能非常有益。
展开▼
